Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) has posted year over year net profit growth of 0.88877.  The net profit number is the nuts and bolts of a firm’s financial health.  Healthy and consistent net profit growth provide investors with confidence that the firm will continue to be profitable and result in the share price moving in a positive direction.  On the other hand, consistent negative numbers could raise serious red flags for shareholders or potential shareholders.

Every individual investor strives to make the best possible stock investment decisions. New investors may have a limited knowledge of how the stock market functions. Studying the basics and accumulating as much knowledge as possible can help the investor create a cornerstone for future success. Everybody has to start somewhere, but continually adding to the market education pool might help the investor see something that they might not have noticed before. Taking a view of the stock market from various angles can help build a more robust databank from which to work from. Because market environments are always shifting, investors may need to do a little extra homework in order to stay ahead of the curve.

When looking to find solid stocks with smooth upward momentum, investors can take a look at the 125/250 day adjusted slope indicator. At the time of writing Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) have a current value of -42.46304. The point of this calculation is to calculate a longer term average adjusted slope value that smooths out large stock price movements by using the average of the timeframe. This indicator is useful in helping find stocks that have been on an even upward trend over the past 6 months to a year.

Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) of the Pharmaceuticals & Biotechnology sector closed the recent session at 18.310000 with a market value of $848133.

Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) has a current suggested portfolio rate of 0.01770 (as a decimal) ownership. Target weight is the volatility adjusted recommended position size for a stock in your portfolio. The maximum target weight is 7% for any given stock. The indicator is based off of the 100 day volatility reading and calculates a target weight accordingly. The more recent volatility of a stock, the lower the target weight will be. The 3-month volatility stands at 67.513000 (decimal). This is the normal returns and standard deviation of the stock price over three months annualized.

Investing in the stock market comes with inherent risk. Some stocks are much riskier than others, but there will always be some level of risk no matter which stocks are chosen. Individual investors managing their own portfolios are constantly on the lookout for investing tips or some kind of information that may confirm their gut feeling about a certain stock. Investors may want to be wary when listening to stock investment advice from friends, family members, or even trusted colleagues. People are usually quick to tell others about the winning stocks that they have picked in the past, but they may not be very forthcoming about discussing those portfolio clunkers. After hearing about the next big stock, investors can always do the research and check the prospect out for themselves.


In looking at some Debt ratios, Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) has a debt to equity ratio of 0.05536 and a Free Cash Flow to Debt ratio of -14.762277. This ratio provides insight as to how high the firm’s total debt is compared to its free cash flow generated. In terms of Net Debt to EBIT, that ratio stands at 0.84489. This ratio reveals how easily a company is able to pay interest and capital on its net outstanding debt. The lower the ratio the better as that indicates that the company is able to meet its interest and capital payments. Lastly we’ll take note of the Net Debt to Market Value ratio. Atara Biotherapeutics, Inc.’s ND to MV current stands at -0.261545. This ratio is calculated as follows: Net debt (Total debt minus Cash ) / Market value of the company.

In looking at some key ratios we note that the Piotroski F Score stands at 2 (1 to 10 scale) and the ERP5 rank holds steady at 17058. The Q.I. Value of Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) currently reads 89.00000 on the Quant scale. The Free Cash Flow score of 0.064796 is also swinging some momentum at investors. The United States of America based firm is currently valued at 14609.

The investing world can be an exciting yet scary place. It is an ever-changing environment filled with profits, losses, and everything in-between. There are always new challenges waiting right around the corner for the individual investor. Just when things seem stable and steady, some unexpected event can send markets into a tizzy. Most investors try hard to create a stock portfolio that can stand on its own during the stormy periods. Unsettling market conditions come with the territory, but knowing how to deal with these conditions can separate the winners from the losers over the long run.  

Some other notable ratios include the Accrual Ratio of -3.656284, the Altman Z score of 11.864855, a Montier C-Score of -1.00000 and a Value Composite rank of 88. Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) has Return on Invested Capital of -2.650120, with a 5-year average of -2.958569 and an ROIC quality score of -1.893514.  Why is ROIC important? It’s one of the most fundamental metrics in determining the value of a given stock.  It helps potential investors determine if the firm is using it’s invested capital to return profits.

Investing in the stock market offers the potential for big returns. On the flip side, investors can also experience major losses when trading equities. Investors are typically trying their best to maximize returns while limiting losses. Figuring out the best way to do this is no easy proposition. There may be periods where everything seems to be working out, and the returns are rolling in. There may be other times when nothing seems to be going right, and the losses start to pile up. Nobody can predict with pinpoint certainty which way the market will shift in the future. Preparing the portfolio for multiple scenarios can help the investor stick it out when the waters get choppy. Having a properly diversified stock portfolio may help investors ride out the turbulence when it inevitably takes control of the market.